A clinical study on the maintenance treatment of platinum-sensitive recurrent ovarian cancer patients who have previously received PARPi, combined with epalrestat and torvelinabucelumab rechallenge

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: b171c89d9f5ae4033d7bf430020d0e15baeaf96e
First added on: Oct 10, 2026